At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,184 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-vascular Risk Factor
In Brief
An observational study for Hypertension. Completed, enrolled 3,184 participants across 120 sites in 3 countries.
Detailed Summary
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesEgypt, Saudi Arabia, United Arab Emirates
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedJul 2009
Primary CompletionNov 2010
TodayJul 2026
First PostedJul 9, 2009
Enrollment StartMay 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.0 years ago